These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28941925)

  • 1. Dynamic Patterns of Testosterone Levels in Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study.
    Xu X; Zhang X; Zhong Y; Saad F; Perez-Patron MJ; Haider K; Haider A
    J Urol; 2018 Feb; 199(2):465-473. PubMed ID: 28941925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.
    Rhoden EL; Riedner CE; Morgentaler A
    J Urol; 2008 May; 179(5):1741-4. PubMed ID: 18343420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
    J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
    Morote J; Ramirez C; Gómez E; Planas J; Raventós CX; de Torres IM; Catalán R
    BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone therapy may reduce prostate cancer risk due to testosterone deficiency at a young age via stabilizing serum testosterone levels.
    Zhang X; Zhong Y; Saad F; Haider KS; Haider A; Clendenin AG; Xu X
    Aging Male; 2020 Jun; 23(2):112-118. PubMed ID: 30857458
    [No Abstract]   [Full Text] [Related]  

  • 8. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review.
    Shabsigh R; Crawford ED; Nehra A; Slawin KM
    Int J Impot Res; 2009; 21(1):9-23. PubMed ID: 18633357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Testosterone and the prostate].
    Sperling H; Rossi R; Lümmen G; Rübben H
    Urologe A; 2004 Sep; 43(9):1092-6. PubMed ID: 15368045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
    Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
    J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
    Morote J; Planas J; Ramirez C; Gómez E; Raventós CX; Placer J; Catalán R; de Torres IM
    BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
    Kaufman JM; Graydon RJ
    J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.
    Gray H; Seltzer J; Talbert RL
    Am J Health Syst Pharm; 2015 Apr; 72(7):536-41. PubMed ID: 25788507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
    Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
    J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between late-onset hypogonadism syndrome plus metabolic syndrome and prostate cancer and its aggressiveness.
    Fuentes-Pastor J; Pellejero P; Ortiz I; Ramírez-Backhaus M; de Gracia A; Marrugo C; Gomez-Ferrer A; Calatrava A; Rubio-Briones J; Rodriguez-Torreblanca C; Solsona-Narbón E
    Actas Urol Esp; 2016 Sep; 40(7):440-5. PubMed ID: 27091367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.
    Watts EL; Appleby PN; Perez-Cornago A; Bueno-de-Mesquita HB; Chan JM; Chen C; Cohn BA; Cook MB; Flicker L; Freedman ND; Giles GG; Giovannucci E; Gislefoss RE; Hankey GJ; Kaaks R; Knekt P; Kolonel LN; Kubo T; Le Marchand L; Luben RN; Luostarinen T; Männistö S; Metter EJ; Mikami K; Milne RL; Ozasa K; Platz EA; Quirós JR; Rissanen H; Sawada N; Stampfer M; Stanczyk FZ; Stattin P; Tamakoshi A; Tangen CM; Thompson IM; Tsilidis KK; Tsugane S; Ursin G; Vatten L; Weiss NS; Yeap BB; Allen NE; Key TJ; Travis RC
    Eur Urol; 2018 Nov; 74(5):585-594. PubMed ID: 30077399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy.
    Parsons JK; Carter HB; Platz EA; Wright EJ; Landis P; Metter EJ
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2257-60. PubMed ID: 16172240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.